Article By:
ChinaBio® Today
Saturday, April 2, 2022 12:45 PM EDT
RemeGen, a Yantai biotech with a portfolio of antibody and dual therapies, completed a $410 million IPO on the Shanghai Star Exchange. Although the offering was oversubscribed, the company’s stock slipped 10% lower in the first two days of trading.